CVS Health (NYSE:CVS) Sets New 1-Year High on Strong Earnings

CVS Health Corporation (NYSE:CVS) shares hit a new 52-week high on Wednesday following a stronger than expected earnings report. The stock traded as high as $88.63 and last traded at $87.8530, with a volume of 2539539 shares. The stock had previously closed at $80.69.

The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.97 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.1%. The ex-dividend date was Thursday, April 23rd. CVS Health’s payout ratio is currently 192.75%.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q1 earnings and revenue beat — CVS reported adjusted EPS of $2.57 (vs. $2.21 consensus) and revenue of $100.43B, topping estimates and marking a fifth consecutive quarterly beat for the company. Read More.
• Positive Sentiment: Raised FY‑2026 guidance — management raised adjusted EPS guidance to $7.30–$7.50 (above consensus ~7.16) and lifted cash‑flow guidance, reducing near‑term execution risk and improving street earnings visibility. Read More.
• Positive Sentiment: Insurance unit turnaround — Aetna’s medical benefit ratio improved to ~84.6% from 87.3% a year earlier, signaling better medical-cost control and driving a large portion of the beat. This directly supports margin recovery for the most volatile segment. Read More.
• Positive Sentiment: Pharmacy benefit moves to cut drug spend — CVS Caremark will expand adoption of lower‑cost interchangeable biosimilars (and will prefer those over some reference brands starting July 1), supporting lower drug costs and client savings for PBM flows. Read More.
• Positive Sentiment: Analyst and price‑target moves — HSBC nudged its price target higher (from $83 to $85), reflecting growing confidence in the company’s trajectory; analyst upgrades/target lifts add to buying pressure. Read More.
• Neutral Sentiment: Strategic/innovation updates — CVS Health Ventures made a small strategic investment in Fathom (autonomous coding) and other items (affiliations, clinic expansions) were reported; these are longer‑term operational items with limited near‑term EPS impact. Read More.
• Neutral Sentiment: Media/preview coverage — several previews and industry pieces highlighted Medicare Advantage exposure and cost trends; useful context but not new catalysts versus the confirmed results above. Read More.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CVS. Leerink Partners reaffirmed an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Piper Sandler decreased their price objective on CVS Health from $101.00 to $99.00 and set an “overweight” rating for the company in a research note on Tuesday, March 31st. Wolfe Research decreased their price objective on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. Bank of America decreased their price objective on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, January 27th. Finally, TD Cowen reaffirmed a “buy” rating on shares of CVS Health in a research report on Friday, March 13th. Twenty equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average target price of $94.61.

Hedge Funds Weigh In On CVS Health

Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd raised its stake in shares of CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares in the last quarter. Swiss RE Ltd. acquired a new stake in shares of CVS Health in the 4th quarter worth approximately $26,000. Sankala Group LLC acquired a new stake in shares of CVS Health in the 4th quarter worth approximately $28,000. Global Trust Asset Management LLC grew its holdings in shares of CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after acquiring an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. acquired a new stake in shares of CVS Health in the 4th quarter worth approximately $28,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Trading Up 7.2%

The firm has a market cap of $110.86 billion, a price-to-earnings ratio of 62.76, a PEG ratio of 0.86 and a beta of 0.60. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. The business has a fifty day moving average of $76.40 and a two-hundred day moving average of $77.96.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.